P R Eisenberg
Overview
Explore the profile of P R Eisenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Latacha M, Schaiff W, Eisenberg P, Abendschein D
J Thromb Haemost
. 2004 Jan;
2(1):128-34.
PMID: 14717976
Activation of the contact system in patients treated with fibrinolytic agents may be an important source of thrombin that activates thrombin-activated fibrinolysis inhibitor (TAFI) and attenuates fibrinolysis. Factor (F)XIIa in...
2.
Tardiff B, Jennings L, Harrington R, Gretler D, Potthoff R, Vorchheimer D, et al.
Circulation
. 2001 Jul;
104(4):399-405.
PMID: 11468200
Background: Platelet deposition and aggregation are central to the pathogenesis of ischemic complications of acute coronary syndromes (ACS). Pharmacodynamic effects of the platelet glycoprotein IIb/IIIa antagonist eptifibatide have been delineated...
3.
Ghigliotti G, Mereto E, Eisenberg P, Martelli A, Orsi P, Sini D, et al.
Thromb Haemost
. 2001 May;
85(4):724-9.
PMID: 11341511
Background: Procoagulant activity and oxidative stress generated by balloon injury to normal vessels promote the migration of medial smooth muscle cells and their proliferation in the intima. We hypothesised that...
4.
Levy N, Liapis H, Eisenberg P, Botney M, Trulock E
J Heart Lung Transplant
. 2001 Mar;
20(3):381-4.
PMID: 11257567
No abstract available.
5.
Abendschein D, Baum P, Verhallen P, Eisenberg P, Sullivan M, Light D
J Pharmacol Exp Ther
. 2001 Feb;
296(2):567-72.
PMID: 11160645
Inhibition of factor Xa (FXa) attenuates thrombus progression. This study was designed to determine whether a novel, synthetic inhibitor of FXa (ZK-807834, molecular mass 527 Da, K(i) = 0.11 nM)...
6.
Ghigliotti G, Eisenberg P, Barsotti A, Spallarossa P, Olivotti L, De Ferrari L, et al.
Ital Heart J
. 2000 Sep;
1 Suppl 3:S32-3.
PMID: 11003018
No abstract available.
7.
Armaganian L, Kam G, Eisenberg P, Schechtman K, Abendschein D
Coron Artery Dis
. 2000 Aug;
11(6):481-7.
PMID: 10966134
Background: Production of oxygen free radicals, and activation of neutrophils and plasma complement contribute to myocardial reperfusion injury, but the role of coagulation has not been assessed. Objective: To characterize...
8.
Abendschein D, Baum P, Martin D, Vergona R, Post J, Rumennik G, et al.
J Cardiovasc Pharmacol
. 2000 May;
35(5):796-805.
PMID: 10813384
Inhibition of factor Xa (FXa) may interrupt thrombus progression. This study compared the antithrombotic activity of a novel FXa inhibitor, ZK-807834 [MW, 527 D; Ki (human FXa), 0.11 nM], with...
9.
Kollef M, Zahid M, Eisenberg P
Crit Care Med
. 2000 Mar;
28(2):414-20.
PMID: 10708176
Objective: To evaluate the performance of a new, rapid semi-quantitative assay for the detection of circulating D-dimer in whole blood from critically ill patients with suspected venous thromboembolic disease. Design:...
10.
Mahaffey K, Puma J, Barbagelata N, DiCarli M, Leesar M, Browne K, et al.
J Am Coll Cardiol
. 1999 Nov;
34(6):1711-20.
PMID: 10577561
Objectives: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would reduce myocardial infarct size. Background: Reperfusion...